MSD Closes Exclusive Global License Agreement for LM-299, An Investigational Anti-PD-1/VEGF Bispecific Antibody from LaNova Medicines Ltd.

MSD (tradename of Merck & Co., Inc., Rahway, N.J., USA) today announced the closing of the exclusive global license agreement for LM-299, a novel investigational PD-1/VEGF bispecific antibody, from LaNova Medicines Ltd. MSD will develop, manufacture and commercialize LM-299. Read more.